Stemline planning up to $90 million follow-on

Cancer company Stemline Therapeutics Inc. (NASDAQ:STML) proposed to raise up to $90 million in a follow-on underwritten by JPMorgan; Jefferies; Aegis Capital; Roth Capital Partners; Ladenburg Thalmann; and H.C. Wainwright. Stemline raised $33.2 million through the sale of 3.3 million shares at $10 in an IPO in January. Stemline closed off $2.70 to $35.20 on Friday, which is a 252% premium to its IPO price. ...